CN1524577A - Alkaline fibroblast growth factor pellicle and its production method - Google Patents
Alkaline fibroblast growth factor pellicle and its production method Download PDFInfo
- Publication number
- CN1524577A CN1524577A CNA031138454A CN03113845A CN1524577A CN 1524577 A CN1524577 A CN 1524577A CN A031138454 A CNA031138454 A CN A031138454A CN 03113845 A CN03113845 A CN 03113845A CN 1524577 A CN1524577 A CN 1524577A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- fibroblast growth
- bfgf
- basic fibroblast
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An alkaline desmocyte growth factor film agent comprising, (1) alkaline desmocyte growth factor (bFGF) 0%-1% (W/W) of effective wound treatment dose, (2) medicinal film forming material 10%-90% (W/W), (3) medicinal findings 0%-50% (W/W), and the process of preparation comprises the steps of, dispersing the medicinal film forming material into distilled water, after sufficient swelling, heat pressing sterilization, dissolving the bFGF stock solution and medical dressing in distilled water, asepsis filtering, charging the filter liquor into disinfected film matrix, stirring slowly and evenly, the bFGF film agent can be obtained through film coating, drying and demoulding.
Description
Technical field
The present invention relates to basic fibroblast growth factor (Basic Fibroblast GrowthFactor is called for short bFGF) membrane and preparation method thereof, utilize this membrane can treat various body surface damages, gynaecopathia, multiple keratopathy and oral ulcer.
Background technology
Basic fibroblast growth factor (bFGF) is a kind of very polypeptides matter of trace that exists in mammal and the human body.BFGF can stimulate mesoderm and the cell in ectoderm source such as the division and the propagation of fibroblast, vascular endothelial cell, smooth muscle cell, corneal epithelial cell, lens epithelial cell, myocyte, osteocyte and neurocyte etc., therefore its physiological function is very extensive, be a kind of multi-functional cell growth factor, mainly show as clinically multiple tissue injury had and promote to repair and the healing effect.At present, be applied to clinical basic fibroblast growth factor (bFGF) preparation and mainly contained rb-bFGF spray and eye drop, the chronic difficulty that burn and scald, fresh wound surface and a variety of causes cause of being respectively indication corneal epithelial defect and the point-like keratopathy that gonosome table ulcer and a variety of causes cause of healing: recurrent superficial punctate keratopathy and light moderate xerophthalmia, bullous keratitis, corneal abrasion, light moderate chemical burn, operation on cornea and the postoperative healing is bad, the single phlyctenular corneal ulcer of map shape (or trophism) etc.But above-mentioned bFGF liquid preparation exists dosage wayward, and medicine uses defectives such as inconvenience at wound surface poor adhesion and operation back.
Summary of the invention
The object of the invention provides a kind of bFGF membrane, remedies bFGF liquid preparation weak point with it, to satisfy requirement of different patients, improve better bFGF clinically therapeutic effect and enlarge its range of application clinically.
The present invention is achieved in that a kind of basic fibroblast growth factor membrane, comprising:
[1], the basic fibroblast growth factor (bFGF) 0%～1% (W/W) of effective Wound healing and bone regeneration amount
[2], pharmaceutically useful filmogen 10%～90% (W/W)
[3], pharmaceutic adjuvant 0%～50% (W/W)
The polypeptide growth factor that belongs to a class together with described bFGF also has somatomedin (PDGF), transforming growth factor (TGF-α), transforming growth factor (TGF-β), insulin like growth factor (IGF-I and IGF-II) and the nerve growth factor (NGF) in acid fibroblast growth factor (aFGF), epithelical cell growth factor (EGF), platelet source, all can be used as the alternative bFGF of somatomedin and makes corresponding membrane.
Described pharmaceutically useful filmogen can be by one or more replacements of following material: PVA, starch, dextrin, cellulose, gelatin, collagen, Lac, arabic gum, agar, alginic acid, zein, cellulose derivative, polyethylene amine, polyethylene amido-acetal derivant, polyvinylpyrrolidone (PVP), polyvinyl pyridine derivant etc.
Described medical dressing can comprise protective agent, plasticizer, surfactant, filler, antiseptic.
Described protective agent can be chosen the human albumin.
Described plasticizer, one or more the mixture that can choose following material constitutes: glycerol, sorbitol,
Dioctyl phthalate.
Described surfactant, one or more the mixture that can choose following material constitutes: Tween 80, lecithin, sodium lauryl sulphate.
Described filler, one or more the mixture that can choose following material constitutes: mannitol, starch, calcium carbonate (CaCO3), silicon dioxide (SiO2).
Described antiseptic, one or more the mixture that can choose following material constitutes: ethyl hydroxybenzoate, sodium benzoate, sorbic acid, methyl hydroxybenzoate, propylparaben, butoben.
Proportioning is as follows more specifically:
(1) basic fibroblast growth factor (bFGF) 0%～1% (W/W) of effective Wound healing and bone regeneration amount
(2) pharmaceutically useful filmogen PVA, its concentration is 10%～90% (W/W)
(3) bFGF protective agent human albumin, its concentration is 0%～10% (W/W)
(4) pharmaceutically useful plasticizer glycerol, its concentration are 0%～20% (W/W)
(5) pharmaceutically useful surfactant Tween 80, its concentration are 0%～2% (W/W)
(6) pharmaceutically useful filler mannitol, its concentration are 0%～20% (W/W)
(7) pharmaceutically useful antiseptic ethyl hydroxybenzoate, its concentration are 0.05%～0.15% (W/W)
Preparation method:
Pharmaceutically useful filmogen is scattered in the distilled water, fully after the swelling, standby behind the pressure sterilizing; BFGF stock solution and medical dressing are dissolved in the distilled water, and solution aseptic filtration adds filtrate in the sterilized membrane substrate, slowly stir, through film, dry, demoulding promptly obtains the bFGF membrane.The every cm of bFGF membrane
2Contain bFGF in 1ng～1 * 10
4Between the ng.
In clinical practice in the past, we find that bFGF spray and eye drop are used for the injury place and run off easily, and dosage is wayward, can influence drug effect.Thereby we make membrane with bFGF, make it to possess good wound surface adhesiveness, the convenient use, and dosage is controlled easily.Be mainly used in treatment burn and scald, fresh wound surface, chronic ulcer, corneal wound, oral ulcer, cervical erosion etc.It is that substrate prepares the bFGF membrane that the present invention adopts PVA.The film property of PVA and the tensile strength of film, flexibility, hygroscopicity and water solublity etc. are all very good; toxicity and the zest of PVA are all very little simultaneously; its solution is to ocular tissue's nonirritant; can form layer protecting film at anterior corneal surface; and can not hinder the regeneration of corneal epithelium; PVA is difficult for also being difficult for growing mycete by microbial destruction.
Description of drawings
Accompanying drawing is a preparation method flow chart of the present invention.
Specific implementation of the present invention
The present invention is illustrated with following embodiment:
Embodiment: bFGF external membrane
1. write out a prescription:
rb-bFGF 0.3mg
Human albumin 30mg
PVA-124 (polyvinyl alcohol) 10g
Glycerol 2g
Tween 80 2g
Mannitol 2g
Ethyl hydroxybenzoate 20mg
Distilled water is an amount of
2. preparation method: (as shown in the figure)
(1) PVA is scattered in an amount of distilled water, fully after the swelling, heating makes dissolving fully, and 121 ℃ of pressure sterilizings are 30 minutes again, and are standby.
(2) recipe quantity ethyl hydroxybenzoate, Tween 80, mannitol and glycerol are dissolved in an amount of distilled water, add bFGF stock solution and human albumin, solution is with 0.22 μ m filter membrane aseptic filtration.
(3) (2) are added in (1), slowly stir.
(4) utilize into film die and film, put into freeze dryer-40 ℃～37 ℃ temperature programming lyophilization 48 hours, demoulding.
(5) quality arbitration, packing, every cm
2Contain the about 0.2 μ g of bFGF.
Described one-tenth film die, freeze dryer equipment are general equipment.
Claims (11)
1, a kind of basic fibroblast growth factor membrane comprises:
(1). the basic fibroblast growth factor (bFGF) 0%～1% (W/W) of effective Wound healing and bone regeneration amount
(2). pharmaceutically useful filmogen 10%～90% (W/W)
(3). pharmaceutic adjuvant 0%～50% (W/W)
2, basic fibroblast growth factor membrane according to claim 1 is characterized in that medical dressing comprises protective agent, plasticizer, surfactant, filler, antiseptic, remover.
3, basic fibroblast growth factor membrane according to claim 1 is characterized in that concrete component is:
(1) basic fibroblast growth factor (bFGF) 0%～1% (W/W) of effective Wound healing and bone regeneration amount
(2) pharmaceutically useful filmogen PVA, its percentage by weight are 10%～90% (W/W)
(3) bFGF protective agent human albumin, its percentage by weight is 0%～10% (W/W)
(4) pharmaceutically useful plasticizer glycerol, its percentage by weight are 0%～20% (W/W)
(5) pharmaceutically useful surfactant Tween 80, its percentage by weight are 0%～2% (W/W)
(6) pharmaceutically useful filler mannitol, its percentage by weight are 0%～20% (W/W)
(7) pharmaceutically useful antiseptic ethyl hydroxybenzoate, its percentage by weight are 0.05%～0.15% (W/W)
4,, it is characterized in that wherein pharmaceutically useful filmogen can choose one or more formations of following material: PVA, starch, dextrin, cellulose, gelatin, collagen, Lac, arabic gum, agar, alginic acid, zein, cellulose derivative, polyethylene amine, polyethylene amido-acetal derivant, polyvinylpyrrolidone (PVP), polyvinyl pyridine derivant according to claim 1 or 3 described basic fibroblast growth factor membrane.
5, according to claim 1 or 3 described basic fibroblast growth factor membrane, it is characterized in that plasticizer, one or more the mixture that can choose following material constitutes: glycerol, sorbitol,
Dioctyl phthalate.
6, according to claim 1 or 3 described basic fibroblast growth factor membrane, it is characterized in that surfactant, one or more the mixture that can choose following material constitutes: Tween 80, lecithin, sodium lauryl sulphate.
7,, it is characterized in that wherein pharmaceutically useful filler also can be by one or more replacements of following material: starch, CaCO according to claim 1 or 3 described basic fibroblast growth factor membrane
3, SiO
2
8, according to claim 1 or 3 described basic fibroblast growth factor membrane, it is characterized in that antiseptic, one or more the mixture that can choose following material constitutes: ethyl hydroxybenzoate, sodium benzoate, sorbic acid, methyl hydroxybenzoate, propylparaben, butoben.
9, basic fibroblast growth factor membrane according to claim 1, its preparation method is: pharmaceutically useful filmogen is scattered in the distilled water, fully after the swelling, standby behind the pressure sterilizing; BFGF stock solution and medical dressing are dissolved in the distilled water, and solution aseptic filtration adds filtrate in the sterilized membrane substrate, slowly stir, through film, dry, demoulding promptly obtains the bFGF membrane.
10, preparation method according to claim 9 is characterized in that drying can adopt lyophilization, dry naturally or heat drying.
11, preparation method according to claim 9 is characterized in that the every cm of bFGF membrane
2Contain bFGF in 1ng～1 * 10
4Between the ng.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113845 CN1267151C (en) | 2003-02-27 | 2003-02-27 | Alkaline fibroblast growth factor pellicle and its production method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113845 CN1267151C (en) | 2003-02-27 | 2003-02-27 | Alkaline fibroblast growth factor pellicle and its production method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1524577A true CN1524577A (en) | 2004-09-01 |
| CN1267151C CN1267151C (en) | 2006-08-02 |
Family
ID=34283823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03113845 Expired - Lifetime CN1267151C (en) | 2003-02-27 | 2003-02-27 | Alkaline fibroblast growth factor pellicle and its production method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1267151C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341494C (en) * | 2005-09-30 | 2007-10-10 | 上海第二医科大学附属第九人民医院 | Eye wrinkle-removing film patch |
| CN1953765B (en) * | 2004-05-12 | 2011-02-09 | 东亚制药株式会社 | An agent comprising FGF2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease |
| CN101721682B (en) * | 2009-11-10 | 2013-01-23 | 苏州金盟生物技术有限公司 | Application of recombinant human fibroblast growth factor 7 mutant in preparing medicament for treating cervical erosion |
| CN104109254A (en) * | 2014-07-10 | 2014-10-22 | 四川大学 | I-type collagen-sodium alginate-polyvinyl alcohol composite film and preparation method thereof |
| CN104258456A (en) * | 2014-08-29 | 2015-01-07 | 华南理工大学 | Wound repair gel containing hexagonal mesoporous silicon and preparation method thereof |
| CN104490851A (en) * | 2014-12-31 | 2015-04-08 | 成都山信药业有限公司 | Iseganan quick-release film agent |
| CN107158363A (en) * | 2017-05-16 | 2017-09-15 | 张莎莎 | A kind of reparation liquid for being used to treat cervical erosion |
| CN113813451A (en) * | 2021-10-20 | 2021-12-21 | 北京大学口腔医学院 | Preparation method and equipment of autologous concentrated growth factor membrane |
-
2003
- 2003-02-27 CN CN 03113845 patent/CN1267151C/en not_active Expired - Lifetime
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1953765B (en) * | 2004-05-12 | 2011-02-09 | 东亚制药株式会社 | An agent comprising FGF2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease |
| US8030274B2 (en) | 2004-05-12 | 2011-10-04 | Dong-A Pharmaceutical Co., Ltd. | Method for treating asthma and chronic obstructive pulmonary disease (COPD) comprising administering FGF2 |
| CN100341494C (en) * | 2005-09-30 | 2007-10-10 | 上海第二医科大学附属第九人民医院 | Eye wrinkle-removing film patch |
| CN101721682B (en) * | 2009-11-10 | 2013-01-23 | 苏州金盟生物技术有限公司 | Application of recombinant human fibroblast growth factor 7 mutant in preparing medicament for treating cervical erosion |
| CN104109254A (en) * | 2014-07-10 | 2014-10-22 | 四川大学 | I-type collagen-sodium alginate-polyvinyl alcohol composite film and preparation method thereof |
| CN104109254B (en) * | 2014-07-10 | 2017-02-22 | 四川大学 | I-type collagen-sodium alginate-polyvinyl alcohol composite film and preparation method thereof |
| CN104258456A (en) * | 2014-08-29 | 2015-01-07 | 华南理工大学 | Wound repair gel containing hexagonal mesoporous silicon and preparation method thereof |
| CN104258456B (en) * | 2014-08-29 | 2016-06-22 | 华南理工大学 | A kind of wound repair gel containing hexagonal mesoporous silicon and preparation method thereof |
| CN104490851A (en) * | 2014-12-31 | 2015-04-08 | 成都山信药业有限公司 | Iseganan quick-release film agent |
| CN104490851B (en) * | 2014-12-31 | 2017-05-24 | 成都山信药业有限公司 | Iseganan quick-release film agent |
| CN107158363A (en) * | 2017-05-16 | 2017-09-15 | 张莎莎 | A kind of reparation liquid for being used to treat cervical erosion |
| CN113813451A (en) * | 2021-10-20 | 2021-12-21 | 北京大学口腔医学院 | Preparation method and equipment of autologous concentrated growth factor membrane |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1267151C (en) | 2006-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Bioactive inorganic/organic nanocomposites for wound healing | |
| US5503848A (en) | Spongy material consisting essentially of hyaluronic acid or its derivatives, and its use in microsurgery | |
| EP0459378B1 (en) | Gels in the form of highly hydrated self-supporting film, the process for their preparation, and their use in the therapy of cutaneous lesions and/or pathologies | |
| TWI445555B (en) | Dressing comprising active components of centella asiatica and use of the same | |
| JP7109097B2 (en) | Histatin for corneal wound healing and ocular surface disease | |
| CN109125799A (en) | GelMA hydrogel people takes off the preparation method of the three-dimensional double-deck auxiliary material of cell amnion | |
| EP1084716A2 (en) | Dressing for the controlled release of active substances to wounds and method for its manufacture | |
| MX2010007282A (en) | Mucosal tissue dressing and method of use. | |
| JP2012162561A (en) | Pharmaceutical composition for topical use in form of xerogel or film and method for production | |
| RU2422133C1 (en) | Hydrophylic gel, method of its obtaining (versions), wound covering and based on it bandage means | |
| BRPI0717734B1 (en) | METHOD FOR PREPARING A DRY POWDER FROM POLYMERIC NANOParticles, DRY POWDER AND USE | |
| JPS60122568A (en) | Hydrophilic biopolymer copolyelectrolyte | |
| Yao et al. | Acceleration of wound healing in traumatic ulcers by absorbable collagen sponge containing recombinant basic fibroblast growth factor | |
| CN1267151C (en) | Alkaline fibroblast growth factor pellicle and its production method | |
| CN105012960A (en) | Film-forming gel composition, application and wound protecting material | |
| JP2022551482A (en) | Eye sealant and method of use | |
| RU2296569C2 (en) | Preparation for healing wound and prevention bandage sticking to wound | |
| Liu et al. | Dual-light defined in situ oral mucosal lesion therapy through a mode switchable anti-bacterial and anti-inflammatory mucoadhesive hydrogel | |
| Singh et al. | Natural polymer-based thin film strategies for skin regeneration in lieu of regenerative dentistry | |
| CN107929810B (en) | Layer-by-layer self-assembled film and preparation method and application thereof | |
| RU2281088C2 (en) | Porous spongy cellulose material for wound treatment | |
| JP2005263759A (en) | Skin penetrable sheet | |
| CN116983287A (en) | American cockroach adhesive film agent for promoting wound repair and preparation method and application thereof | |
| CN110903510A (en) | Preparation method of visible light copolymerization crosslinked porous mesh GelMA-dHAMMA hydrogel | |
| Khokhlenkova | Prospects of using biopolymeric films in medicine and pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060802 |
|
| CX01 | Expiry of patent term |